Ginsenosides Rh1, Rg2, and Rg3 ameliorate dexamethasone-induced muscle atrophy in C2C12 myotubes.

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Exogenous synthetic glucocorticoids like dexamethasone (Dex) can induce muscle atrophy.
• Muscle atrophy is characterized by reduced muscle mass and function, impacting overall health.
• Identifying effective therapeutic agents for muscle atrophy is crucial.

Purpose of the Study:

• To investigate the anti-atrophic effects of ginsenosides Rh1, Rg2, and Rg3 on dexamethasone-induced C2C12 myotube atrophy.
• To elucidate the molecular mechanisms underlying the protective effects of these ginsenosides.

Main Methods:

• C2C12 myotubes were treated with dexamethasone to induce atrophy.
• Cell viability was assessed using XTT assays.
• Myotube diameter and fusion index were measured.
• Protein expression levels of key signaling molecules were analyzed via Western blot.

Main Results:

• Ginsenosides Rh1, Rg2, and Rg3 enhanced cell viability in dexamethasone-treated myotubes.
• These ginsenosides increased myotube diameter and fusion index, counteracting dexamethasone-induced atrophy.
• Rh1, Rg2, and Rg3 downregulated atrophy-related proteins (FoxO3a, MuRF1, Fbx32).
• They upregulated mitochondrial biogenesis via the SIRT1/PGC-1α pathway and modulated the IGF-1/Akt/mTOR pathway.

Conclusions:

• Ginsenosides Rh1, Rg2, and Rg3 demonstrate significant anti-atrophic effects against dexamethasone-induced muscle wasting.
• These compounds protect C2C12 myotubes by regulating key signaling pathways involved in muscle protein synthesis and degradation.
• Rh1, Rg2, and Rg3 hold promise as therapeutic agents for preventing and treating muscle atrophy.